Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers
09 Novembro 2023 - 6:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, and Johns Hopkins University jointly
announced today the execution of an exclusive license agreement.
Exagen will focus on the development of novel patented biomarkers
for therapeutic management of patients with lupus nephritis.
Under the terms of the license agreement, Exagen will acquire a
worldwide exclusive license to an invention from the laboratory of
Michelle Petri, MD, MPH, and Andrea Fava, MD. Exagen intends to
develop the novel biomarkers into assays to aid diagnostic and
treatment decisions by providing unique clinical insight into a
specific patient’s lupus nephritis in a non-invasive manner.
“We are very excited to accelerate the development of these
highly innovative biomarkers for lupus nephritis patient
management. Exagen has a strong track record of serving clinicians
in the autoimmune space and having the opportunity to work with
this exceptional team further reinforces our commitment to
developing novel technology in this space,” said John Aballi,
President and CEO of Exagen Inc.
About Exagen Inc.
Exagen is a leading provider of autoimmune testing and its
purpose as an organization is to provide clarity in autoimmune
disease decision making with the goal of improving patients’
clinical outcomes. Exagen is located in San Diego County,
California.
For more information, please visit Exagen.com and
follow @ExagenInc on Twitter.
Forward Looking Statements
Exagen cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on Exagen’s
current beliefs and expectations. Such forward-looking statements
include, but are not limited to, statements regarding the expected
benefits of the collaboration with Johns Hopkins University and any
development and commercialization of novel patented biomarkers for
diagnosis, prognosis and monitoring of autoimmune diseases. The
inclusion of forward-looking statements should not be regarded as a
representation by Exagen that any of its plans will be achieved.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in Exagen’s
business, including, without limitation: delays in reimbursement
and coverage decisions from Medicare and third-party payors and in
interactions with regulatory authorities, and delays in ongoing and
planned clinical trials involving its tests; Exagen’s commercial
success depends upon attaining and maintaining significant market
acceptance of its testing products among rheumatologists, patients,
third-party payors and others in the medical community; Exagen’s
ability to successfully execute on its business strategies;
third-party payors not providing coverage and adequate
reimbursement for Exagen’s testing products, including Exagen’s
ability to collect on funds due; Exagen’s ability to obtain and
maintain intellectual property protection for its testing products;
regulatory developments affecting Exagen’s business; and other
risks described in Exagen’s prior press releases and Exagen’s
filings with the Securities and Exchange Commission (“SEC”),
including under the heading “Risk Factors” in Exagen’s Annual
Report on Form 10-K for the year ended December 31, 2022 and any
subsequent filings with the SEC. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof, and Exagen undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
Investor RelationsExagen Inc.Ryan
Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com
Exagen (NASDAQ:XGN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Exagen (NASDAQ:XGN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024